Ono Pharmaceutical Co., Ltd. (OPHLF)
USD 11.19
(-0.04%)
USD 11.19
(-0.04%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | 127.97 Billion JPY | 13.53% |
| 2023 | 112.72 Billion JPY | 40.0% |
| 2022 | 80.51 Billion JPY | 6.75% |
| 2021 | 75.42 Billion JPY | 26.33% |
| 2020 | 59.7 Billion JPY | 15.84% |
| 2019 | 51.53 Billion JPY | 2.5% |
| 2018 | 50.28 Billion JPY | -9.87% |
| 2017 | 55.79 Billion JPY | 123.36% |
| 2016 | 24.97 Billion JPY | 92.5% |
| 2015 | 12.97 Billion JPY | -36.22% |
| 2014 | 20.34 Billion JPY | -11.24% |
| 2013 | 22.91 Billion JPY | -5.92% |
| 2012 | 24.36 Billion JPY | 0.57% |
| 2011 | 24.22 Billion JPY | -13.11% |
| 2010 | 27.87 Billion JPY | 17.3% |
| 2009 | 23.76 Billion JPY | -32.19% |
| 2008 | 35.04 Billion JPY | -0.64% |
| 2007 | 35.27 Billion JPY | -2.42% |
| 2006 | 36.14 Billion JPY | -8.08% |
| 2005 | 39.32 Billion JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q4 | 17.43 Billion JPY | -51.64% |
| 2024 Q1 | 31.81 Billion JPY | 86.43% |
| 2024 Q3 | 36.05 Billion JPY | -15.52% |
| 2024 FY | 127.97 Billion JPY | 13.53% |
| 2024 Q2 | 42.67 Billion JPY | 34.12% |
| 2023 Q4 | 17.06 Billion JPY | -48.77% |
| 2023 Q2 | 32.86 Billion JPY | 11.48% |
| 2023 Q1 | 29.47 Billion JPY | 85.4% |
| 2023 FY | 112.72 Billion JPY | 40.0% |
| 2023 Q3 | 33.31 Billion JPY | 1.38% |
| 2022 Q3 | 18.33 Billion JPY | -17.49% |
| 2022 Q4 | 15.89 Billion JPY | -13.26% |
| 2022 FY | 80.51 Billion JPY | 6.75% |
| 2022 Q1 | 24.07 Billion JPY | 169.34% |
| 2022 Q2 | 22.21 Billion JPY | -7.72% |
| 2021 Q2 | 18.35 Billion JPY | -14.62% |
| 2021 Q1 | 21.49 Billion JPY | 172.9% |
| 2021 FY | 75.42 Billion JPY | 26.33% |
| 2021 Q4 | 8.93 Billion JPY | -66.45% |
| 2021 Q3 | 26.63 Billion JPY | 45.14% |
| 2020 Q3 | 19.01 Billion JPY | 15.32% |
| 2020 FY | 59.7 Billion JPY | 15.84% |
| 2020 Q4 | 7.87 Billion JPY | -58.57% |
| 2020 Q2 | 16.48 Billion JPY | 0.96% |
| 2020 Q1 | 16.33 Billion JPY | 94.27% |
| 2019 Q2 | 13.6 Billion JPY | -10.68% |
| 2019 Q3 | 14.28 Billion JPY | 4.99% |
| 2019 FY | 51.53 Billion JPY | 2.5% |
| 2019 Q4 | 8.4 Billion JPY | -41.17% |
| 2019 Q1 | 15.23 Billion JPY | 72.26% |
| 2018 Q4 | 8.84 Billion JPY | -56.28% |
| 2018 Q3 | 20.22 Billion JPY | 114.4% |
| 2018 Q2 | 9.43 Billion JPY | -19.87% |
| 2018 Q1 | 11.77 Billion JPY | -11.61% |
| 2018 FY | 50.28 Billion JPY | -9.87% |
| 2017 Q4 | 13.32 Billion JPY | -31.17% |
| 2017 FY | 55.79 Billion JPY | 123.36% |
| 2017 Q2 | 9.43 Billion JPY | -31.0% |
| 2017 Q1 | 13.68 Billion JPY | 135.94% |
| 2017 Q3 | 19.35 Billion JPY | 105.04% |
| 2016 Q4 | 5.79 Billion JPY | -20.66% |
| 2016 Q1 | 9.45 Billion JPY | 446.01% |
| 2016 Q2 | 2.42 Billion JPY | -74.4% |
| 2016 FY | 24.97 Billion JPY | 92.5% |
| 2016 Q3 | 7.3 Billion JPY | 201.98% |
| 2015 Q2 | 373 Million JPY | -87.17% |
| 2015 FY | 12.97 Billion JPY | -36.22% |
| 2015 Q4 | -2.73 Billion JPY | -121.99% |
| 2015 Q3 | 12.42 Billion JPY | 3231.37% |
| 2015 Q1 | 2.9 Billion JPY | 48.75% |
| 2014 FY | 20.34 Billion JPY | -11.24% |
| 2014 Q2 | 3.53 Billion JPY | -55.73% |
| 2014 Q3 | 8.35 Billion JPY | 136.09% |
| 2014 Q4 | 1.95 Billion JPY | -76.6% |
| 2014 Q1 | 7.99 Billion JPY | 151.37% |
| 2013 Q3 | 9.86 Billion JPY | 272.27% |
| 2013 FY | 22.91 Billion JPY | -5.92% |
| 2013 Q1 | 8.42 Billion JPY | 25.95% |
| 2013 Q4 | 3.17 Billion JPY | -67.79% |
| 2013 Q2 | 2.65 Billion JPY | -68.52% |
| 2012 Q4 | 6.68 Billion JPY | -28.05% |
| 2012 Q3 | 9.29 Billion JPY | 25013.51% |
| 2012 Q2 | 37 Million JPY | -99.56% |
| 2012 Q1 | 8.34 Billion JPY | 60.02% |
| 2012 FY | 24.36 Billion JPY | 0.57% |
| 2011 Q1 | 8.32 Billion JPY | 153.26% |
| 2011 Q2 | 1 Billion JPY | -87.95% |
| 2011 Q4 | 5.21 Billion JPY | -46.13% |
| 2011 FY | 24.22 Billion JPY | -13.11% |
| 2011 Q3 | 9.68 Billion JPY | 865.2% |
| 2010 Q1 | 11.17 Billion JPY | 283.59% |
| 2010 FY | 27.87 Billion JPY | 17.3% |
| 2010 Q2 | 4.73 Billion JPY | -57.59% |
| 2010 Q3 | 8.67 Billion JPY | 83.12% |
| 2010 Q4 | 3.28 Billion JPY | -62.13% |
| 2009 FY | 23.76 Billion JPY | -32.19% |
| 2009 Q2 | 5.16 Billion JPY | 0.0% |
| 2009 Q4 | 2.91 Billion JPY | -58.21% |
| 2009 Q3 | 6.97 Billion JPY | 35.03% |
| 2008 FY | 35.04 Billion JPY | -0.64% |
| 2007 FY | 35.27 Billion JPY | -2.42% |
| 2006 FY | 36.14 Billion JPY | -8.08% |
| 2005 FY | 39.32 Billion JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AstraZeneca PLC | 5.95 Billion USD | -2049.068% |
| Bristol-Myers Squibb Company PFD CONV 2 | 8.02 Billion USD | -1494.729% |
| CSPC Pharmaceutical Group Limited | 830.91 Million USD | -15301.913% |
| Clarus Therapeutics Holdings, Inc. | -56.51 Million USD | 226559.867% |
| Novartis AG | 14.85 Billion USD | -761.798% |
| PT Kalbe Farma Tbk. | 179.7 Million USD | -71114.832% |